Lucid Capital Markets analyst Elemer Piros assumes coverage on Nuvectis Pharma (NASDAQ: NVCT) with a Buy rating and a price ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments New Coverage